Back to search results

Shingrix Vaccine for Shingles After Stem Cell Transplant

This study is looking at how well the Shingrix vaccine works in people who have had an allogeneic (donor) stem cell transplant. Shingles is a painful rash caused by the chickenpox virus, and people who have had a stem cell transplant are at a higher risk of getting it. This study will give the Shingrix vaccine to eligible patients between one and three years after their transplant. Researchers will measure how strongly your body's immune system (its defense against illness) responds to the vaccine. The goal is to see if the vaccine can help prevent shingles in this group of patients. This study is currently unclear on its recruitment status.

Study design
This is a Phase II interventional study that plans to enroll 100 participants. It is a non-randomized study.
What's involved
You would receive the Shingrix vaccine. The study will measure your immune response one month after your last vaccine dose.
Compensation
Not stated in the trial record.
Follow-up
Your immune response will be measured one month after your last vaccine dose.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05554068

Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Recruiting
PHASE2All AgesInterventionalTreatment
Loyola University
~100 participants
Updated 2023-03-08 on ClinicalTrials.gov
What's tested:Shingrix

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Cell mediated and humoral immune response
Measured over Measured one month following eh last dose of vaccine received

Conditions

Shingles

Explore related trials

Acute LeukemiaChronic Lymphocytic LeukemiaChronic Myeloid Leukemia, BCR-ABL1 PositiveHematologic NeoplasmHodgkin's GranulomaMultiple MyelomaMyelodysplastic SyndromeMyeloproliferative disorderNon-Hodgkin Lymphoma

Where it's being run

1 sites across 1 states
Illinois1

Who to contact

Patrick A Hagen
[email protected]
708-327-3810
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥18 years
≥ 12 months and ≤ 36 months post-AlloSCT
Donor sources: matched related, matched unrelated, cord blood
Any malignant hematological disease including acute leukemia, myelodysplastic syndrome, non-Hodgkin's lymphoma, Hodgkin's lymphoma, chronic lymphocytic leukemia, chronic myeloid leukemia, multiple myeloma, and myeloproliferative disorders.
Any conditioning regimen
Any planned immunosuppressive prophylactic regimen
Patients with chronic graft-versus-host disease on stable immunosuppression
Ability to understand and the willingness to sign a written informed consent.
Negative pregnancy test in female patients of childbearing potential

Exclusion

Patients who had zoster after an allogeneic transplant and prior to enrollment
Patients who are currently pregnant
History of allergic reactions attributed to compounds of similar chemical or biologic composition to the recombinant zoster vaccine, Shingrix, or other agents used in study.
Patients who have had a relapse of their primary hematological disease
Previous allogeneic stem cell transplantation
Acute disease at the time of vaccination
Thrombocytopenia that in the judgment of the investigator would make intramuscular injection unsafe.

What this trial measures

  • Cell mediated and humoral immune responseMeasured one month following eh last dose of vaccine received